China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts
This article was originally published in PharmAsia News
SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing
You may also be interested in...
China State FDA Urges Manufacturers To Abandon Some Projects Ahead Of GMP Implementation - DIA China Conference
BEIJING - China's new good manufacturing practices guidelines for pharmaceuticals officially came into effect March 1, and China's State FDA is now trying to educate domestic companies on how they can implement the new standards. One bit of advice being offered is: "Give up.
Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China
SHANGHAI - The world's largest pharmaceutical company Pfizer Inc. and China's second-largest distributor Shanghai Pharmaceutical Holdings Co. Ltd announced April 21 a memorandum of understanding to explore business opportunities, including the potential to jointly register, commercialize and distribute in China an innovative compound from Pfizer
SHANGHAI - China's contract manufacturing market, the world's largest supplier of bulk drug materials, is expected to reach a value of roughly $2 billion in FY2010, according to consulting firm Frost & Sullivan